DENVER--(BUSINESS WIRE)--Ceragenix Pharmaceuticals, Inc. (OTCBB:CGXP) (the "Company"), a biopharmaceutical and medical device company focused on infectious disease and dermatology, today announced that Cohen Independent Research Group (www.cohenresearch.com) has initiated coverage of the Company with a Strong Buy recommendation. The report covers the Company’s platform technologies in the treatment of atopic dermatitis (eczema) and antimicrobial coatings for medical devices.
